知镜 Cognispect · 医学文献与研究工作台

Comparison of scoring systems in the identification of transthyretin cardiac amyloidosis in a HFpEF cohort.

Scully TG, Cai P, Hare J, Nogic J, Sajeev JK, Kaye D, Gibbs S, Wisniowski B, Ting SB.
International journal of cardiology · 2026-10-07 · PMID 42843460

文献摘要

Background Multiple diagnostic scoring systems have been developed to improve the identification of patients with transthyretin cardiac amyloidosis (ATTR-CA) in patients presenting with heart failure with preserved ejection fraction (HFpEF). The ATTR-CM, AMY, T-Amylo and AMYLI scores have been validated, though data comparing their performance are lacking. We sought to compare the diagnostic accuracy of the scores in an Australian cohort. Methods We conducted a retrospective cohort study across two separate healthcare centres from 2018 to 2024 comprising all patients diagnosed with ATTR-CA and all consecutive patients presenting to a HFpEF clinic who were screened for ATTR-CA. All scores were calculated retrospectively. A multivariable logistic regression model was used to identify significant variables. Results A total of 430 patients were included with ATTR-CA being diagnosed in 116 patients (27.0%). The T-Amylo score (area under the curve: 0.895; 95% CI 0.861-0.929) and ATTR-CM score (area under the curve of 0.883; 95% CI 0.847-0.918) both demonstrated very good discriminative capacity for ATTR-CA while the AMY score displayed a moderate discriminative capacity (area under the curve of 0.745; 95% CI 0.689-0.802). In a cohort restricted to patients with increased wall thickness, the AMYLI score displayed a moderate discriminative capacity (area under the curve of 0.777; 95% CI 0.721-0.833). Conclusions Both the ATTR-CM and T-Amylo scores displayed very good performance in identifying patients at high risk for ATTR-CA in patients with known HFpEF.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。